Annexon (ANNX) Cash from Investing Activities (2019 - 2026)
Annexon's (ANNX) quarterly Cash from Investing Activities came in at $27.1 million in Q1 2026, down 72.28% year-on-year from $97.6 million in Q1 2025, and up 202.02% quarter-over-quarter from -$26.5 million in Q4 2025.
Annexon (ANNX) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Annexon's Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $27.1 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 72.28% year-over-year to $27.1 million in Q1 2026; TTM through Mar 2026 was $119.5 million, a 372.34% increase from a year earlier, with the FY2025 full-year figure at $190.1 million, up 186.86% from the prior year.
- Cash from Investing Activities grew to $27.1 million in Q1 2026 per ANNX's latest filing, from -$26.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $97.6 million in Q1 2025 and bottomed at -$96.6 million in Q2 2024.
- The 5-year median for Cash from Investing Activities is $14.1 million (2022), against an average of $7.5 million.
- Across the five-year window, Cash from Investing Activities surged 1203.13% in 2022 and plunged 2720.65% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$43.6 million in 2022, then soared by 94.99% to -$2.2 million in 2023, then jumped by 146.36% to $1.0 million in 2024, then plunged by 2720.65% to -$26.5 million in 2025, then soared by 202.02% to $27.1 million in 2026.
- Per Business Quant, the three latest ANNX Cash from Investing Activities figures stand at $27.1 million (Q1 2026), -$26.5 million (Q4 2025), and $45.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Annexon | 1.03 Bn | 1.03 Bn | - | 27.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.06 Mn |
| Mar 31, 2026 | 27.06 Mn |
| Dec 31, 2025 | -26.52 Mn |
| Dec 31, 2025 | -26.52 Mn |
| Sep 30, 2025 | 45.87 Mn |
| Sep 30, 2025 | 45.87 Mn |
| Jun 30, 2025 | 73.08 Mn |
| Jun 30, 2025 | 73.08 Mn |
| Mar 31, 2025 | 97.62 Mn |
| Mar 31, 2025 | 97.62 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | -45.93 Mn |
| Sep 30, 2024 | -45.93 Mn |
| Jun 30, 2024 | -96.58 Mn |
| Jun 30, 2024 | -96.58 Mn |
| Mar 31, 2024 | -77.30 Mn |
| Mar 31, 2024 | -77.30 Mn |
| Dec 31, 2023 | -2.18 Mn |
| Dec 31, 2023 | -2.18 Mn |